These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 12499923)
1. Effect of cholecystokinin1 receptor antagonist loxiglumide (CR1505) on basal pancreatic exocrine secretion in conscious rats. Ishizaki K; Kinbara S; Kawamura M; Kimura K; Shiratori K; Takeuchi T Pancreas; 2003 Jan; 26(1):87-91. PubMed ID: 12499923 [TBL] [Abstract][Full Text] [Related]
2. Effects of loxiglumide on pancreatic exocrine secretion stimulated by cholecystokinin-8 in conscious dogs. Ninomiya K; Saito T; Wakatsuki K; Saeki M; Kato T; Kasai H; Kimura K; Fujii M Arzneimittelforschung; 1998 Jan; 48(1):52-4. PubMed ID: 9522032 [TBL] [Abstract][Full Text] [Related]
3. Effects of loxiglumide on pancreatic exocrine secretion stimulated by meal in conscious dogs. Ninomiya K; Saito T; Wakatsuki K; Saeki M; Kato T; Edano K; Kasai H; Kimura K; Fujii M Arzneimittelforschung; 1998 Jan; 48(1):55-7. PubMed ID: 9522033 [TBL] [Abstract][Full Text] [Related]
4. Effect of chronic oral administration of the CCK receptor antagonist loxiglumide on exocrine and endocrine pancreas in normal rats. Imoto I; Yamamoto M; Jia DM; Otsuki M Int J Pancreatol; 1997 Dec; 22(3):177-85. PubMed ID: 9444548 [TBL] [Abstract][Full Text] [Related]
5. Treatment with cholecystokinin receptor antagonist loxiglumide enhances insulin response to intravenous glucose stimulation in postpancreatitic rats. Otsuki M; Nakano S; Tachibana I Regul Pept; 1994 Jul; 52(2):85-95. PubMed ID: 7972939 [TBL] [Abstract][Full Text] [Related]
6. Effect of the cholecystokinin receptor antagonist loxiglumide on pancreatic exocrine function in rats after acute pancreatitis. Nakano S; Tachibana I; Otsuki M Pancreas; 1995 Apr; 10(3):287-94. PubMed ID: 7542770 [TBL] [Abstract][Full Text] [Related]
7. CCK administration after CCK receptor blockade accelerates recovery from cerulein-induced acute pancreatitis in rats. Nakano S; Kihara Y; Otsuki M Pancreas; 1998 Mar; 16(2):169-75. PubMed ID: 9510141 [TBL] [Abstract][Full Text] [Related]
8. Loxiglumide. A new proglumide analog with potent cholecystokinin antagonistic activity in the rat pancreas. Otsuki M; Fujii M; Nakamura T; Okabayashi Y; Tani S; Fujisawa T; Koide M; Baba S Dig Dis Sci; 1989 Jun; 34(6):857-64. PubMed ID: 2470557 [TBL] [Abstract][Full Text] [Related]
9. Duration of anti-cholecystokinin (CCK) action on the rat exocrine pancreas of new CCK receptor antagonist FK480 administered orally. Moriyoshi Y; Shiratori K; Iwabe C; Watanabe S; Takeuchi T J Gastroenterol; 1996 Apr; 31(2):249-53. PubMed ID: 8680546 [TBL] [Abstract][Full Text] [Related]
10. Effects of proglumide on cholecystokinin-8-induced exocrine and endocrine pancreatic responses in conscious sheep. Mineo H; Iwaki N; Kogishi K; Onaga T; Kato S; Zabielski R Comp Biochem Physiol A Physiol; 1997 Nov; 118(3):759-64. PubMed ID: 9406447 [TBL] [Abstract][Full Text] [Related]
11. Comparison of loxiglumide, a cholecystokinin receptor antagonist, and atropine on hormonal and meal-stimulated pancreatic secretion in man. Gabryelewicz A; Kulesza E; Konturek SJ Scand J Gastroenterol; 1990 Jul; 25(7):731-8. PubMed ID: 2396088 [TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of the cholecystokinin antagonist loxiglumide on pancreatic exocrine secretion and pancreatic growth in conscious rats. Taguchi S; Green GM; Nakano I; Hatta Y Int J Pancreatol; 1992 Apr; 11(2):67-73. PubMed ID: 1607730 [TBL] [Abstract][Full Text] [Related]
13. Biochemical and pharmacological profiles of loxiglumide, a novel cholecystokinin-A receptor antagonist. Fukamizu Y; Nakajima T; Kimura K; Kanda H; Fujii M; Saito T; Kasai H Arzneimittelforschung; 1998 Jan; 48(1):58-64. PubMed ID: 9522034 [TBL] [Abstract][Full Text] [Related]
14. Effects of cholecystokinin receptor antagonist loxiglumide on rat exocrine pancreas. Nakano S; Tachibana I; Otsuki M Pancreas; 1994 Jul; 9(4):425-33. PubMed ID: 7937691 [TBL] [Abstract][Full Text] [Related]
15. Role of endogenously released cholecystokinin in determining postprandial insulin levels in man: effects of loxiglumide, a specific cholecystokinin receptor antagonist. Baum F; Nauck MA; Ebert R; Cantor P; Hoffmann G; Choudhury AR; Schmidt WE; Creutzfeldt W Digestion; 1992; 53(3-4):189-99. PubMed ID: 1291406 [TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of two cholecystokinin-receptor antagonists, loxiglumide and L-364,718, on the pancreatic secretory response to intraduodenal tryptophan in dogs. Niebergall-Roth E; Teyssen S; Wetzel D; Hartel M; Beglinger C; Riepl RL; Singer MV Scand J Gastroenterol; 1996 Jul; 31(7):723-32. PubMed ID: 8819225 [TBL] [Abstract][Full Text] [Related]
18. Effects of the cholecystokinin A receptor antagonist loxiglumide on the proliferation and cell cycle time of pancreatic acinar cells in rats. Kanemitsu D; Sakagami J; Motoyoshi T; Nakajima T; Kataoka K Pancreas; 2006 Mar; 32(2):190-6. PubMed ID: 16552340 [TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan. Shiratori K; Takeuchi T; Satake K; Matsuno S; Pancreas; 2002 Jul; 25(1):e1-5. PubMed ID: 12131781 [TBL] [Abstract][Full Text] [Related]
20. Inhibitory effect of intraduodenal infusion of loxiglumide on pancreatic exocrine secretion. Tanikawa M; Hayakawa T; Kondo T; Shibata T; Kitagawa M; Kodaira T; Hamaoka T Arzneimittelforschung; 1993 Jan; 43(1):35-9. PubMed ID: 8447844 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]